Format

Send to

Choose Destination
Curr Opin Pharmacol. 2003 Aug;3(4):420-5.

JNK: a new therapeutic target for diabetes.

Author information

1
Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA. bbennett@celgene.com

Abstract

Jun N-terminal kinase (JNK) regulates the transcription factor AP-1, which is implicated in the controlled expression of many genes involved in the immune response. For this reason, drug discovery efforts have focused on the development of JNK inhibitors for chronic inflammatory diseases. However, recent genetic evidence and emerging pharmacological data indicate that activated JNK could be critical in causing diabetes, insulin resistance and obesity. Indeed, if JNK is considered as a stress-activated protein kinase, there appear to be multiple mechanisms through which it might promote diabetes.

PMID:
12901952
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center